The Fda stated it was restricting the use of Johnson & Johnson’s JNJ COVID-19 vaccine for older people thanks to the hazard of a unusual blood clotting syndrome.
The J&J shot can be administered in instances in which authorized or permitted COVID-19 vaccines are not available, or if an particular person is fewer eager on making use of the other two photographs, the Fda claimed.
The Food and drug administration mentioned the threat of TTS warranted limiting the use of the single-dose shot just after it investigated described situations.
The enterprise has current the U.S. COVID-19 vaccine simple fact sheet to alert about the hazard of thrombosis with thrombocytopenia syndrome (TTS), a exceptional but most likely existence-threatening issue.
Final thirty day period, JNJ suspended its forecast for COVID-19 vaccine income, citing a glut of source.
TTS circumstances, which involve blood clots accompanied by a small degree of platelets, have beforehand been documented in recipients of the J&J vaccine.
The Fda in January amended the fact sheet for the J&J vaccine to include the threat of immune thrombocytopenia.
The U.S. Facilities for Ailment Manage and Prevention had suggested that People pick to get mRNA shots from Pfizer Inc PFE / BioNTech SE BNTX and Moderna Inc MRNA above J&J’s vaccine because of to the unusual instances of blood clotting.
Price Action: JNJ shares closed 1.11% decrease at $175.00 all through soon after-several hours trading on Thursday.
Photo through Wikimedia Commons